Auriga Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.88 M
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth -1.69%
- Profit Growth -19.24%
- Ebitda 11.48%
- Net Worth 171.96%
- Total Assets 19.28%
About Auriga Life Sciences
Auriga Life Sciences Private Limited (ALSPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 July 2013 and has a history of 11 years and six months. Its registered office is in Ernakulam, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.88 M, as per Ministry of Corporate Affairs (MCA) records.
Subramonia Hariharan, Vinodkumar Madhavan, Binu Varghese, and One other member serve as directors at the Company.
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232KL2013PTC034650
- Company No.
034650
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jul 2013
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Auriga Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinodkumar Madhavan  | Managing Director | 30-Jul-2013 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Subramonia Hariharan | Director | 30-Jul-2013 | Current |
| Binu Varghese | Additional Director | 02-Sep-2021 | Current |
| Ramadil Unni | Additional Director | 02-Sep-2021 | Current |
Financial Performance of Auriga Life Sciences.
Auriga Life Sciences Private Limited, for the financial year ended 2019, experienced Minor drop in revenue, with a 1.69% decrease. The company also saw a substantial fall in profitability, with a 19.24% decrease in profit. The company's net worth Soared by an impressive increase of 171.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Auriga Life Sciences?
In 2019, Auriga Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Auriga Life Sciences?
Unlock and access historical data on people associated with Auriga Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Auriga Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Auriga Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
